| Ytd | -5.99% | |
| 1y | -23.71% |
| Open | 5.34 | Prev Close | 5.34 | Low | 5.34 | High | 5.34 | Mkt Cap | 35.98M |
| Vol | 551.92K | Avg Vol | 82.01K | EPS | -9.37 | P/E | -0.57 | Forward P/E | -0.99 |
| Beta | 2.82 | Short Ratio | 8.96 | Inst. Own | 82.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.52 | 200-d Avg | 5.11 | 1yr Est | 7.50 |
GBIO News
INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd.,
Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has earned an average rating of "Hold" from the
Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has been assigned an average rating of "Hold" fr
MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GB
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation B
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnolo
Generation Bio (NASDAQ: GBIO - Get Free Report) and Nuvation Bio (NYSE: NUVB - Get Free Report) are
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Dir
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading afte
Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consens
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ev
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnolo
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnolog
Squarepoint Ops LLC purchased a new position in Generation Bio Co. (NASDAQ:GBIO – Free Report)
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consens
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnolo
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consens
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T c